DigiPath Labs CSO Dr. Cindy Orser Authors Article on Cannabis Safety for Cannabis Nurses Magazine

LAS VEGAS, March 31, 2016 /PRNewswire/ -- Dr. Cindy Orser, the Chief Science Officer of DigiPath Labs—a subsidiary of DigiPath, Inc. (OTCQB: DIGP)—recently authored the lead article in Cannabis Nurses Magazine. In her article, Dr. Orser, who has been an outspoken proponent of raising cannabis safety standards, explains what patients and nurses alike need to know about cannabis testing, methods of administration, and medicinal effects.

"It is an honor to contribute my knowledge to Cannabis Nurses Magazine," says Dr. Orser. "Cannabis nurses are some of the most dedicated members of the medical cannabis industry, always eager to access the latest knowledge about cannabinoid medicine and share it with their patients."

Dr. Orser's article, "Safety of Medical Cannabis Products: What Every Patient Should Know," covers important patient safety topics including uniform testing standards, the endocannabinoid system, cannabis administration, and the medicinal function of various compounds found in the cannabis plant.

Dr. Orser's article appears in the March/April issue of Cannabis Nurses Magazine, which focuses on safety and testing. The issue is available in print or online at https://issuu.com/hempnation/docs/march-april-cnm-2016/7?e=11924549/33878051.

To learn more about DigiPath Labs, visit www.digipathlabs.com.

About DigiPath, Inc.

DigiPath, Inc., supports the cannabis industry's best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath's two business units are DigiPath Labs and TNM News Corp.

For more information, go to www.digipath.com.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
DigiPath, Inc.
Investor Relations
702.470.2249
[email protected]

Logo - http://photos.prnewswire.com/prnh/20151118/288714LOGO

SOURCE DigiPath, Inc.

Related Links

http://www.digipath.com